索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]韩拓,蒋伟.非ST段抬高型急性冠脉综合征药物治疗进展[J].国际心血管病杂志,2025,01:36-38，46.
点击复制

非ST段抬高型急性冠脉综合征药物治疗进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2025年01期
页码:
36-38，46
栏目:
综述
出版日期:
2025-01-25

文章信息/Info

Title:
-
作者:
韩拓; 蒋伟
710004 西安交通大学第二附属医院心血管内科
Author(s):
-
关键词:
非ST段抬高型急性冠脉综合征; P2Y12受体抑制剂; 基因多态性; 秋水仙碱
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2025.01.010
文献标识码:
-
摘要:
非ST段抬高型急性冠脉综合征（NSTE-ACS）包括非ST段抬高型心肌梗死与不稳定型心绞痛，其诊治流程相似，疾病群体差异较大。中国最新《非ST段抬高型急性冠脉综合征诊断和治疗指南》为NSTE-ACS患者提供了规范有效的临床诊治路径。该文介绍指南中P2Y12受体抑制剂选择与基因分型检测、前蛋白转化酶枯草溶菌素9抑制剂启用时机以及抗炎治疗的最新进展，以期助力临床实践。
Abstract:
-

参考文献/References

[1] 刘明波, 王增武, 樊静, 等. 《中国心血管健康与疾病报告2023》要点解读[J]. 中国心血管病研究, 2024, 22(7):577-593.
[2] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会.非ST段抬高型急性冠脉综合征诊断和治疗指南（2024）[J].中华心血管病杂志, 2024, 52(6):615-646.
[3] Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med, 2009, 361(11):1045-1057.
[4] Patti G, Micieli G, Cimminiello C, et al. The role of clopidogrel in 2020: a reappraisal[J]. Cardiovasc Ther, 2020, 2020:8703627.
[5] Kim HK, Tantry US, Smith SCJ, et al. The East Asian paradox:an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease[J]. Thromb Haemost, 2021, 121(4):422-432.
[6] Qiu MH, Na K, Qi ZZ, et al. Contemporary use of ticagrelor vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GRACE risk score stratification-based analysis in a large-scale, real-world study from China[J]. Mayo Clin Proc, 2023, 98(7):1021-1032.
[7] Gimbel M, Qaderdan K, Willemsen L, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial[J]. Lancet, 2020, 395(10233):1374-1381.
[8] Pereira NL, Cresci S, Angiolillo DJ, et al. CYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association[J]. Circulation, 2024, 150(6):e129-e150.
[9] Wang YJ, Meng X, Wang AX, et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA[J]. N Engl J Med, 2021, 385(27):2520-2530.
[10] Rosenson RS, Hegele RA, Fazio S, et al. The evolving future of PCSK9 inhibitors[J]. J Am Coll Cardiol, 2018, 72(3):314-329.
[11] Hummelgaard S, Vilstrup JP, Gustafsen C, et al. Targeting PCSK9 to tackle cardiovascular disease[J]. Pharmacol Ther, 2023, 249:108480.
[12] O'Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease[J]. Circulation, 2022, 146(15):1109-1119.
[13] Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med, 2018, 379(22):2097-2107.
[14] Averna M, Banach M, Bruckert E, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a European Atherosclerosis Society Task Force[J]. Atherosclerosis, 2021, 325:99-109.
[15] Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J, 2021, 42(14):1289-1367.
[16] Gallego-Colon E, Daum A, Yosefy C. Statins and PCSK9 inhibitors: a new lipid-lowering therapy[J]. Eur J Pharmacol, 2020, 878:173114.
[17] 王增武, 刘静, 李建军, 等. 中国血脂管理指南（2023年）[J].中国循环杂志, 2023, 38(3):237-271.
[18] Chung J, Kim HL, Lim WH, et al. New onset diabetes mellitus and cardiovascular outcomes according to statin intensity in patients after drug-eluting stent implantation in Asian patients[J]. Sci Rep, 2023, 13(1):16061.
[19] Marfella R, Prattichizzo F, Sardu C, et al. Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque[J]. Atherosclerosis, 2023, 378:117180.
[20] Schremmer J, Busch L, Baasen S, et al. Chronic PCSK9 inhibitor therapy leads to sustained improvements in endothelial function, arterial stiffness, and microvascular function[J]. Microvasc Res, 2023, 148:104513.
[21] Qi ZY, Hu L, Zhang JJ, et al. PCSK9 (proprotein convertase subtilisin/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36[J]. Circulation, 2021, 143(1):45-61.
[22] Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med, 2019, 381(26):2497-2505.
[23] Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease[J]. N Engl J Med, 2020, 383(19):1838-1847.
[24] Li JJ, Meng X, Shi FD, et al. Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3):multicentre, double blind, randomised, placebo controlled trial[J]. BMJ, 2024, 385:e079061.
[25] Deftereos SG, Beerkens FJ, Shah B, et al. Colchicine in cardiovascular disease: in-depth review[J]. Circulation, 2022, 145(1):61-78.

备注/Memo

备注/Memo:
基金项目：西安市科技计划 （24YXYJ0148）；西安交通大学第二附属医院科研基金青年项目[YJ（QN）202325]
通信作者：蒋伟， E-mail：xnkjiangwei@163.com
更新日期/Last Update: 2025-02-10